摘要
新型冠状病毒病已呈全球大流行态势。迄今仍未发现针对该病的特异性抗病毒药物,所有治疗均基于实验和同情用药,由于缺乏大规模临床研究支持,在临床给药中须格外注意药物不良反应。既往研究显示药物不良反应除受年龄、性别、地域等外在因素影响外,还与患者的基因背景密切相关。国家卫生健康委员会发布的《新型冠状病毒肺炎诊疗方案》(试行第七版)给出了若干指导性药物,本文就该方案中提示的药物相关基因多态性做一综述。
Coronavirus disease 2019(COVID-19) has gradually evolved into a global pandemic. Up to now,there is no specific antiviral medication available for COVID-19 treatment, and all treatments are based on experimental or compassionate use. The adverse drug reactions and potential drug interactions should be pay attention in clinical administration. Previous studies have shown the adverse drug reactions are closely related to the patient’s genetic background except the age, gender, and region. This paper reviewed the progress in drug-related gene polymorphisms for the treatment of COVID-19.
作者
张微
郭楠
杨曦明
ZHANG Wei;GUO Nan;YANG Xi-Ming(Department of Clinical Laboratory,Dongzhimen Hospital,Beijing University of Chinese Medicine,Beijing 100700,China)
出处
《生物技术通讯》
CAS
2020年第3期346-351,共6页
Letters in Biotechnology
基金
中央高校基本科研业务费专项资金(2019-JYB-JS-049)。
